vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.

AVADEL PHARMACEUTICALS PLC is the larger business by last-quarter revenue ($77.5M vs $71.1M, roughly 1.1× RE/MAX Holdings, Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs 0.0%, a 2.0% gap on every dollar of revenue. On growth, AVADEL PHARMACEUTICALS PLC posted the faster year-over-year revenue change (54.9% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $22.2M). Over the past eight quarters, AVADEL PHARMACEUTICALS PLC's revenue compounded faster (99.6% CAGR vs -4.7%).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.

AVDL vs RMAX — Head-to-Head

Bigger by revenue
AVDL
AVDL
1.1× larger
AVDL
$77.5M
$71.1M
RMAX
Growing faster (revenue YoY)
AVDL
AVDL
+56.7% gap
AVDL
54.9%
-1.8%
RMAX
Higher net margin
RMAX
RMAX
2.0% more per $
RMAX
2.0%
0.0%
AVDL
More free cash flow
RMAX
RMAX
$11.3M more FCF
RMAX
$33.5M
$22.2M
AVDL
Faster 2-yr revenue CAGR
AVDL
AVDL
Annualised
AVDL
99.6%
-4.7%
RMAX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
AVDL
AVDL
RMAX
RMAX
Revenue
$77.5M
$71.1M
Net Profit
$20.0K
$1.4M
Gross Margin
Operating Margin
2.5%
13.1%
Net Margin
0.0%
2.0%
Revenue YoY
54.9%
-1.8%
Net Profit YoY
100.8%
-75.2%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
RMAX
RMAX
Q4 25
$71.1M
Q3 25
$77.5M
$73.2M
Q2 25
$68.1M
$72.8M
Q1 25
$52.5M
$74.5M
Q4 24
$50.4M
$72.5M
Q3 24
$50.0M
$78.5M
Q2 24
$41.5M
$78.5M
Q1 24
$27.2M
$78.3M
Net Profit
AVDL
AVDL
RMAX
RMAX
Q4 25
$1.4M
Q3 25
$20.0K
$4.0M
Q2 25
$9.7M
$4.7M
Q1 25
$-4.9M
$-2.0M
Q4 24
$-5.0M
$5.8M
Q3 24
$-2.6M
$966.0K
Q2 24
$-13.8M
$3.7M
Q1 24
$-27.3M
$-3.4M
Gross Margin
AVDL
AVDL
RMAX
RMAX
Q4 25
Q3 25
Q2 25
90.7%
Q1 25
89.4%
Q4 24
90.5%
Q3 24
87.7%
Q2 24
93.3%
Q1 24
94.4%
Operating Margin
AVDL
AVDL
RMAX
RMAX
Q4 25
13.1%
Q3 25
2.5%
25.0%
Q2 25
13.0%
19.3%
Q1 25
-5.7%
7.2%
Q4 24
-6.5%
5.9%
Q3 24
-0.7%
19.4%
Q2 24
-30.7%
20.6%
Q1 24
-95.8%
5.8%
Net Margin
AVDL
AVDL
RMAX
RMAX
Q4 25
2.0%
Q3 25
0.0%
5.4%
Q2 25
14.2%
6.4%
Q1 25
-9.4%
-2.6%
Q4 24
-10.0%
8.0%
Q3 24
-5.2%
1.2%
Q2 24
-33.3%
4.7%
Q1 24
-100.6%
-4.3%
EPS (diluted)
AVDL
AVDL
RMAX
RMAX
Q4 25
Q3 25
$0.00
Q2 25
$0.10
Q1 25
$-0.05
Q4 24
$-0.04
Q3 24
$-0.03
Q2 24
$-0.14
Q1 24
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
RMAX
RMAX
Cash + ST InvestmentsLiquidity on hand
$91.6M
$118.7M
Total DebtLower is stronger
$432.2M
Stockholders' EquityBook value
$98.2M
$452.4M
Total Assets
$199.4M
$582.5M
Debt / EquityLower = less leverage
0.96×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
RMAX
RMAX
Q4 25
$118.7M
Q3 25
$91.6M
$107.5M
Q2 25
$81.5M
$94.3M
Q1 25
$66.5M
$89.1M
Q4 24
$73.8M
$96.6M
Q3 24
$65.8M
$83.8M
Q2 24
$71.4M
$66.1M
Q1 24
$88.8M
$82.1M
Total Debt
AVDL
AVDL
RMAX
RMAX
Q4 25
$432.2M
Q3 25
$433.3M
Q2 25
$434.4M
Q1 25
$435.3M
Q4 24
$436.2M
Q3 24
$437.2M
Q2 24
$438.1M
Q1 24
$439.0M
Stockholders' Equity
AVDL
AVDL
RMAX
RMAX
Q4 25
$452.4M
Q3 25
$98.2M
$448.1M
Q2 25
$90.7M
$442.4M
Q1 25
$74.1M
$433.5M
Q4 24
$73.8M
$429.5M
Q3 24
$74.7M
$423.1M
Q2 24
$70.3M
$418.4M
Q1 24
$78.4M
$412.0M
Total Assets
AVDL
AVDL
RMAX
RMAX
Q4 25
$582.5M
Q3 25
$199.4M
$582.2M
Q2 25
$187.2M
$574.8M
Q1 25
$167.9M
$571.4M
Q4 24
$164.2M
$581.6M
Q3 24
$158.3M
$578.6M
Q2 24
$157.5M
$571.4M
Q1 24
$167.9M
$566.7M
Debt / Equity
AVDL
AVDL
RMAX
RMAX
Q4 25
0.96×
Q3 25
0.97×
Q2 25
0.98×
Q1 25
1.00×
Q4 24
1.02×
Q3 24
1.03×
Q2 24
1.05×
Q1 24
1.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
RMAX
RMAX
Operating Cash FlowLast quarter
$22.2M
$40.9M
Free Cash FlowOCF − Capex
$22.2M
$33.5M
FCF MarginFCF / Revenue
28.7%
47.1%
Capex IntensityCapex / Revenue
0.0%
10.4%
Cash ConversionOCF / Net Profit
1110.25×
28.39×
TTM Free Cash FlowTrailing 4 quarters
$56.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
RMAX
RMAX
Q4 25
$40.9M
Q3 25
$22.2M
$17.7M
Q2 25
$12.7M
$4.6M
Q1 25
$-8.2M
$5.7M
Q4 24
$7.9M
$59.7M
Q3 24
$-6.9M
$17.6M
Q2 24
$-18.2M
$15.9M
Q1 24
$-29.7M
$9.4M
Free Cash Flow
AVDL
AVDL
RMAX
RMAX
Q4 25
$33.5M
Q3 25
$22.2M
$16.4M
Q2 25
$2.9M
Q1 25
$4.0M
Q4 24
$53.0M
Q3 24
$16.3M
Q2 24
$14.0M
Q1 24
$6.8M
FCF Margin
AVDL
AVDL
RMAX
RMAX
Q4 25
47.1%
Q3 25
28.7%
22.4%
Q2 25
4.0%
Q1 25
5.3%
Q4 24
73.2%
Q3 24
20.8%
Q2 24
17.8%
Q1 24
8.6%
Capex Intensity
AVDL
AVDL
RMAX
RMAX
Q4 25
10.4%
Q3 25
0.0%
1.8%
Q2 25
2.2%
Q1 25
2.3%
Q4 24
9.1%
Q3 24
0.0%
1.7%
Q2 24
2.4%
Q1 24
3.3%
Cash Conversion
AVDL
AVDL
RMAX
RMAX
Q4 25
28.39×
Q3 25
1110.25×
4.45×
Q2 25
1.31×
0.97×
Q1 25
Q4 24
10.28×
Q3 24
18.22×
Q2 24
4.29×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVDL
AVDL

Segment breakdown not available.

RMAX
RMAX

Franchising Segment$50.1M70%
Broker Fees$13.9M20%
Annual Dues$7.4M10%

Related Comparisons